Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

FPIs’ outflow nears Rs 33,000 crore in May on weaker rupee

Published

on

FPIs' outflow nears Rs 33,000 crore in May on weaker rupee
Foreign investors continued to pare their exposure to Indian equities, withdrawing Rs 32,963 crore in May due to weak earnings growth, rupee depreciation and more attractive opportunities in other markets.

With this, the total outflow by Foreign Portfolio Investors (FPIs) from the equity market has reached Rs 2.25 lakh crore in 2026, which is higher than the Rs 1.66 lakh crore pulled out during the entire 2025, according to data with the NSDL.

FPIs were net sellers in all months of 2026, except February. They withdrew Rs 35,962 crore in January before turning net buyers in February, when they invested Rs 22,615 crore, the highest monthly inflow in 17 months.

However, the trend reversed in March, when foreign investors pulled out a record Rs 1.17 lakh crore. The selling continued in April with net outflows of Rs 60,847 crore and extended into May with withdrawals of nearly Rs 33,000 crore.

Advertisement

FPIs have been selling Indian equities due to a combination of weak earnings growth, rupee depreciation and more attractive opportunities in other markets, market experts said. However, the pace of selling has been moderated.


Geojit Investments Chief Investment Strategist V K Vijayakumar said subdued earnings growth in India, compared with significantly stronger corporate performance in markets such as the US, Japan, South Korea and Taiwan, has prompted FPIs to shift capital overseas.
“The strong artificial intelligence-led rally in markets such as South Korea and Taiwan has also attracted foreign capital away from India,” Vijayakumar said.Sachin Jasuja, Head of Equities and Founding Partner at Centricity WealthTech, said the persistent depreciation of the rupee has emerged as another key factor behind FPI outflows.

“The rupee has weakened nearly 6 per cent so far in 2026 and around 10 per cent over the past year, falling from the mid-80s to about 95.5 against the US dollar despite RBI’s efforts to defend the currency,” he said.

Jasuja noted that India’s heavy dependence on crude oil imports has further aggravated concerns. With the country importing more than 80 per cent of its crude requirements, the sharp rise in Brent crude prices from the USD 70 per barrel range to USD 95-105 amid disruptions around the Strait of Hormuz has widened both the import bill and the current account deficit.

“A weaker rupee directly impacts dollar-denominated returns for foreign investors, making it one of the biggest reasons for continued FPI selling,” he said.

Advertisement

The pace of selling has been moderated in May compared to previous months.

Himanshu Srivastava, Principal – Manager Research at Morningstar Investment Research India, said moderation in outflows suggests that foreign investors are becoming less aggressive in reducing their India exposure compared with the heavy selling witnessed earlier in the year.

” One of the key reasons behind this trend has been the gradual improvement in global risk sentiment. Concerns around global trade tensions, tariff-related developments, and growth uncertainties, while still present, have eased somewhat from the elevated levels seen a few months ago,” he added.

On the outlook, Jasuja said a reversal in FPI flows is unlikely in the near term unless there is a significant improvement in macroeconomic conditions.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Solution for May 31, 2026 Puzzle #1807 Sparks Musical Puzzle Discussions

Published

on

Nancy Guthrie

Wordle enthusiasts logging into The New York Times’ popular daily word game on Sunday encountered a musical challenge as the answer for puzzle No. 1807 was revealed as “ETUDE.”

Wordle puzzle
Wordle puzzle

The five-letter word, a term familiar to musicians and classical music aficionados, refers to a short composition designed to practice a specific technique while often holding artistic value. According to Webster’s New World College Dictionary, an etude is “a musical composition for a solo instrument, designed to give practice in some special point of technique, but often performed for its artistic worth.”

Players who started their guesses with common openers like “RAISE” or “TOUCH” found themselves navigating vowel-heavy patterns, as “ETUDE” features three vowels and a repeated “E.” The puzzle’s solution aligned with many players’ experiences of medium difficulty, with solvers frequently reporting four or five attempts.

The Enduring Appeal of Wordle

Since its acquisition by The New York Times in 2022, Wordle has maintained a dedicated global following. The game’s simple premise — guess a five-letter word in six attempts with color-coded feedback — continues to draw millions daily. Green tiles indicate correct letters in the right position, yellow shows correct letters in the wrong spot, and gray eliminates letters entirely.

On May 31, 2026, social media platforms lit up with reactions ranging from satisfaction to playful frustration. Many noted the musical theme as a refreshing departure from more common vocabulary. Puzzle No. 1807 followed Saturday’s solution, “SMILE,” which had generated lighter, more upbeat conversations.

Advertisement

Wordle’s daily reset at midnight local time creates a shared cultural moment across time zones. In Seoul, where many international players participate during evening hours, discussions often blend with local K-pop and classical music communities.

Breaking Down Today’s Puzzle

For those seeking strategic insights, effective starting words for Sunday’s puzzle included those testing multiple vowels early. “ETUDE” begins and ends with “E,” with “T,” “U,” and “D” filling the middle. The repeated “E” added an extra layer for players avoiding duplicate guesses too early.

Hints circulating before the solution included references to music practice pieces and piano studies famously composed by figures like Frédéric Chopin, whose etudes remain staples in conservatory training. One subtle hint shared across gaming sites: “A piece of music.”

The New York Times’ official review for puzzle No. 1807 confirmed the solution and provided context on its linguistic and cultural significance, helping players understand not just the word but its place in artistic lexicon.

Advertisement

Community and Strategy

Wordle solvers often develop personal rituals. Some swear by consonant-heavy openers like “SLATE” or “CRANE,” while others prefer vowel tests with “AUDIO” or “ADIEU.” For Sunday’s puzzle, players who tested “E” early gained an advantage.

Online forums and Reddit threads dedicated to Wordle saw spikes in activity, with users sharing grids and celebrating streaks. One common theme: the satisfaction of connecting everyday gaming with cultural knowledge. “ETUDE” rewarded those with even passing familiarity with music education.

The game’s accessibility — free with a NYT subscription for additional features — has helped sustain its popularity years after its viral peak. Unlike more complex puzzles, Wordle’s daily commitment fosters habit without overwhelming players.

Historical Context and Wordle Milestones

Wordle’s journey from a personal project by software engineer Josh Wardle to a media phenomenon remains remarkable. Launched publicly in 2021, it tapped into a universal desire for simple, satisfying challenges during uncertain times.

Advertisement

By 2026, the game has produced thousands of unique puzzles, each carefully curated by the NYT Games team to balance difficulty and fairness. Puzzle numbers like 1807 mark steady progression, with players tracking personal statistics and global solve rates.

Past May 31 puzzles varied widely, from “MANOR” in earlier years to “CHAOS” and “HABIT” in others, showing the game’s broad vocabulary range.

Tips for Future Success

Experts recommend several strategies for consistent performance:

  • Start with words containing multiple vowels and common consonants.
  • Use information from each guess efficiently — eliminate impossible letters quickly.
  • Consider word frequency and common patterns in English.
  • Avoid repeating eliminated letters.
  • For hard mode, which forces use of known correct letters, practice builds intuition.

Sunday’s puzzle highlighted the value of musical vocabulary. Players unfamiliar with “ETUDE” may have arrived through process of elimination, reinforcing how Wordle gently expands users’ lexicons.

Global Reach and Cultural Impact

In South Korea, Wordle integrates with strong English learning culture and interest in classical music performance. Many students and professionals play during commutes or breaks, turning the daily puzzle into a small educational moment.

Advertisement

The game’s influence extends beyond entertainment. Educators note its value in building vocabulary, pattern recognition and resilience through trial and error. Families compete across generations, creating bonding opportunities.

As artificial intelligence and advanced algorithms influence many games, Wordle’s human-curated simplicity stands out. Each puzzle undergoes review to ensure solvability and appropriateness.

Looking Ahead

Monday’s puzzle awaits, promising another fresh challenge. Wordle’s predictable yet surprising nature keeps players returning. Whether solving in two attempts or stretching to six, the shared experience connects millions.

For those who missed Sunday’s solution, “ETUDE” offered a harmonious end to the weekend — a reminder that even simple games can carry artistic echoes.

Advertisement

The New York Times continues refining the experience with occasional variants and connections to other puzzles like Connections and Mini Crossword. Wordle’s core remains unchanged: a daily invitation to think, guess and learn.

As players reset their streaks and share results with green and yellow emoji grids, the community thrives on collective curiosity. Sunday’s musical answer added a melodic note to the ongoing Wordle story.

Continue Reading

Business

MasterBrand Stock’s Massive Transformation Is A Step To A Brighter Future (NYSE:MBC)

Published

on

MasterBrand Stock's Massive Transformation Is A Step To A Brighter Future (NYSE:MBC)

This article was written by

Daniel is an avid and active professional investor.
He runs Crude Value Insights, a value-oriented newsletter aimed at analyzing the cash flows and assessing the value of companies in the oil and gas space. His primary focus is on finding businesses that are trading at a significant discount to their intrinsic value by employing a combination of Benjamin Graham’s investment philosophy and a contrarian approach to the market and the securities therein. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Marsh & McLennan Stock: 16 Years Of Dividend Growth And Counting (NYSE:MRSH)

Published

on

Marsh & McLennan Stock: 16 Years Of Dividend Growth And Counting (NYSE:MRSH)

This article was written by

Scott Kaufman, aka Treading Softly, learned about investing firsthand from over a decade of financial sector experience. He is the lead analyst for Dividend Kings providing actionable insight into high quality dividend growing and undervalued opportunities. His focus is to see a bountiful harvest of cash dividends and strong capital gains, providing a robust total return.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Kody’s Dividends, Justin Law, and Rachel Kaufman are part of the Dividend Kings team

Advertisement

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Continue Reading

Business

Why Trump is encouraging psychedelics for mental health

Published

on

Why Trump is encouraging psychedelics for mental health
Why Trump is pushing psychedelics research to treat mental illness

Marie Phelan said she had never heard of MDMA before spotting a flyer seeking veterans suffering from post traumatic stress disorder.

Now, she says the psychoactive drug more commonly known as ecstasy or molly has changed the trajectory of her life.

“My experience of MDMA was that it just cracked my heart wide open,” said Phelan who enlisted in the U.S. Army Reserve in 1999 and was deployed to Iraq in 2003.

“I was carrying this big heavy rucksack and I just put it down on the beach and I started unpacking it one little teeny tiny thing at a time and setting each little thing out on the waves,” Phelan said of the release from the treatment.

Advertisement

Phelan isn’t alone turning to alternative treatments for trauma. She is among a small group of Americans who have undergone psychedelic-assisted therapy through clinical trials studying new approaches to mental health treatment.

Now, access to those therapies is closer than ever to being expanded more broadly, bringing new options for patients and opportunities for companies — but also new scrutiny about safety and effectiveness.

In April, President Donald Trump signed an executive order aimed at accelerating research into psychedelic drugs for mental illness. The move came as his administration issued priority review vouchers to three companies developing psychedelic or MDMA-like therapies — Compass Pathways, Usona Institute and Transcend Therapeutics — aimed at speeding up parts of the FDA review process.

The order marks a notable shift in tone from Trump’s first term, when his administration took a harder stance on cannabis and other controlled substances. This time, the White House said psychedelic compounds “show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after after completing standard therapy.”

Advertisement

U.S. President Donald Trump signs an executive order on researching the effects of psychedelic drugs in medical treatment for veterans, on Saturday, April 18, 2026 in the Oval Office at the White House in Washington, D.C.

The Washington Post | The Washington Post | Getty Images

Investors quickly piled into the sector. Shares of psychedelic drug developers such as Compass Pathways and other rivals tied to the space rallied following the announcement, with Wall Street analysts arguing the order could legitimize an industry long viewed as fringe.

The science, however, remains deeply debated, raising questions about how much room the segment has to grow.

Advertisement

Inside the lab

Historically, research into psychedelics has focused more narrowly on certain conditions. Psilocybin — the active compound in psychedelic mushrooms — was tied to treating depression, MDMA-assisted therapy to PTSD and LSD to anxiety.

While drugs like psilocybin and ibogaine — a psychoactive compound derived from a West African shrub that some advocates believe may help treat addiction and traumatic brain injuries — are considered classic psychedelics, MDMA is technically classified as an empathogen.

Still, researchers and regulators often group MDMA-assisted therapy within the broader psychedelic medicine field because the treatments involve supervised therapeutic sessions designed to address conditions like PTSD, depression and addiction.

“One of the things that’s important to recognize is these are all very different drugs,” said Brandon Weiss, a researcher at the Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine. “Ibogaine and other psychedelic compounds have different safety profiles and different risks.”

Advertisement

FILE PHOTO: Psilocybin or “magic mushrooms” are seen in an undated photo provided by the U.S. Drug Enforcement Agency in Washington, May 7, 2019.

DEA | Reuters

Clinical research around some of these compounds has shown promising results. In late-stage trials sponsored by the nonprofit psychedelic research advocacy group Multidisciplinary Association for Psychedelic Studies, roughly 71% of participants with severe PTSD no longer met diagnostic criteria for the disorder after MDMA-assisted therapy sessions.

The FDA rejected a previous application for MDMA-assisted therapy in 2024, citing concerns around the design of that same late-stage study and the need for additional data. Some psychedelic researchers viewed that decision as evidence the agency remains cautious despite mounting public enthusiasm.

Advertisement

Countries outside the United States have already begun loosening restrictions. Australia became the first country to allow authorized psychiatrists to prescribe MDMA and psilocybin for certain mental health conditions in 2023. Researchers in Canada, Switzerland and the United Kingdom have also expanded clinical studies examining psychedelic-assisted therapies.

Even so, Weiss cautions that not all psychedelic compounds carry the same risks — or the same amount of evidence supporting their use.

“Psychedelic compounds, they have different safety profiles, different risks,” said Weiss. “Ibogaine has particularly high cardiovascular risks, and so what needs to be done is a very measured, methodical weighting of the safety and the efficacy between ibogaine and other compounds.”

The White House executive order specifically referenced accelerating research of ibogaine. But unlike psilocybin or MDMA-assisted therapy, ibogaine has not undergone large-scale clinical trials in the United States and has been linked to potentially serious cardiovascular side effects.

Advertisement

Weiss said the real worry among some researchers is not that psychedelic therapies are ineffective, but that political momentum could outpace the scientific process.

“My biggest concern would be that FDA standards are relaxed for politically motivated reasons,” he said. “It’s not clear that that is the case, but what’s required is a lot more scientific research and a very objective interpretation of the risks and benefits.”

Kabir Nath, Compass Pathways CEO, said his company is adhering to the same standards the FDA holds for all drugs. He said the company would not have started the process of submitting its drug, COMP360 Psilocybin, for approval in the first place if it felt the data was insufficient.

Even supporters of psychedelics used as treatment acknowledge the therapies are far more complex than taking a prescription pill at home. Most psychedelic-assisted therapy trials involve hours of preparation with clinicians, supervised treatment sessions and follow-up integration therapy afterward.

Advertisement

The treatments also come with risks. Patients can experience panic attacks, paranoia, elevated heart rates or psychological distress during sessions. In some clinical environments, doctors use so called “rescue drugs” like benzodiazepines or antipsychotic medications to calm patients experiencing severe adverse reactions or overwhelming hallucinations.

Phelan said her own experience with MDMA-assisted therapy felt less like intoxication and more like confronting years of trauma in a controlled setting.

For veterans’ advocates like Juliana Mercer, executive director of nonprofit Healing Breakthrough, the administration’s order represents validation for patients who have spent years pushing for broader access to alternative mental health treatments. Mercer, a U.S. Marine Corps veteran, said psychedelic-assisted therapy “completely changed” her life after she struggled with trauma.

“One of the things that this experience was able to give me was that permission to heal,” said Mercer.

Advertisement

Why now?

As the Trump administration pursues VA staffing cuts and deeper military involvement with Iran, some veterans are increasingly questioning the prioritization of their care.

Thus, some critics of the Trump administration have said that the executive order’s timing is of particular importance as the president attempts to gain back veteran support ahead of the midterm elections.

Phelan, however, rejected the idea that backing for psychedelic therapies will translate into into political support for Trump.

“They’d made so many cuts to veteran benefits and medical services,” Phelan said. “Great, you did a good thing. You did a right thing … I can’t speak for how other people will react, but if that’s the intention, I doubt it’s effective.”

Advertisement

Some industry executives also argue the executive order may have less immediate impact than headlines suggest. Companies like Compass Pathways were already nearing the final stage of Phase 3 trials before the White House announcement, meaning FDA approval submissions were likely coming regardless.

Nath, CEO or Compass Pathways, said the order primarily signals broader political acceptance of the field.

“It certainly gives a significant tailwind, encouragement and validation,” Nath said.

— CNBC’s Ryan Baker contributed to this report

Advertisement
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Zepto shares crash 30% in unlisted market despite Sebi nod for IPO. What’s cooking?

Published

on

Zepto shares crash 30% in unlisted market despite Sebi nod for IPO. What's cooking?
The unlisted shares of Zepto Limited have fallen nearly 30% over the past month despite the company securing regulatory approval for its IPO, highlighting growing caution among investors amid volatile market conditions.

Zepto’s shares, which were changing hands at around Rs 52 in the unlisted market a month ago, have dropped to about Rs 40, according to dealers tracking pre-IPO transactions.

The decline comes even as the quick commerce startup recently received approval from Sebi to launch its much-awaited public issue. The company had taken the confidential route to file the DRHP but may soon file its papers publicly in June, according to Bloomberg.

Analysts said the fall reflects weakness in the unlisted market and a broader reassessment of valuations rather than any company-specific development. The company is being valued at around Rs 38,000 crore in the dealer market.

Advertisement

Several companies that had planned public offerings this year have either delayed listings or adopted a wait-and-watch approach because of volatility in equity markets, geopolitical tensions and uncertainty around investor demand.


The benchmark Nifty has remained under pressure for much of 2026, while foreign institutional investors have continued to remain cautious on Indian equities amid concerns over crude oil prices, global growth and the earnings outlook.
The weakness in the secondary market for pre-IPO shares has also affected several startup names, with investors becoming more selective on valuations after a strong rally in the segment over the past two years.Zepto is preparing for a public market debut that could raise around $1.3 billion, or roughly Rs 11,000-12,000 crore, making it one of the largest internet IPOs since the listing of Swiggy.

If the issue proceeds as planned, Zepto could become the youngest venture-backed Indian startup to enter public markets, just four years after its founding.

The proposed offering is expected to comprise a substantial fresh issue of around Rs 11,000 crore along with an offer-for-sale component by existing investors.

The IPO assumes significance because it comes amid intensifying competition in India’s fast-growing quick commerce sector.

Advertisement

Zepto competes with Blinkit, owned by Eternal, as well as Swiggy Instamart, Flipkart Minutes and Amazon Now.

The listing is also expected to strengthen the company’s balance sheet at a time when the quick commerce industry continues to spend aggressively on expansion, dark stores and customer acquisition.

As of late last year, Zepto had around Rs 7,000 crore in cash, significantly lower than the roughly Rs 17,000-18,000 crore cash reserves reported by listed rivals Eternal and Swiggy.

The company raised $450 million in October last year at a valuation of $7 billion. Following the fundraise, it accelerated customer acquisition efforts through higher discounts and promotional campaigns as competition intensified across major cities.

Advertisement

Zepto had also completed its domicile shift from Singapore to India, a move increasingly adopted by venture-backed startups preparing for domestic listings.

The company has appointed a consortium of investment bankers including Morgan Stanley, HSBC, Goldman Sachs, Axis Capital, JM Financial, IIFL Securities and Motilal Oswal Financial Services to manage the public issue. The IPO is expected to hit the market in the July-September quarter of 2026.

While the recent decline in the unlisted share price may reflect near-term market caution, investors will closely watch the final valuation and broader market conditions when Zepto eventually launches what is expected to be one of the year’s most closely watched public offerings.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Advertisement
Continue Reading

Business

Experimental Novartis radiopharma drug shows promise in early study

Published

on

Experimental Novartis radiopharma drug shows promise in early study


Experimental Novartis radiopharma drug shows promise in early study

Continue Reading

Business

‘Misleading financial statements’: Suzlon to challenge Sebi’s penalty order before SAT

Published

on

'Misleading financial statements': Suzlon to challenge Sebi's penalty order before SAT
Suzlon Energy plans to challenge a recent Sebi order that imposed penalties of nearly Rs 29 crore on the company and several former executives over alleged accounting and disclosure violations. In an exchange filing, Suzlon said it intends to file an appeal before the Securities Appellate Tribunal (SAT) against the regulator’s order dated May 29.

“The findings of Sebi in the said order are related to the financial statements of the company from FY14 to FY18. The company will be filing an appeal before the Securities Appellate Tribunal in respect of the Sebi order,” the company said.

The development comes a day after Sebi imposed penalties on Suzlon and a number of former senior executives following a long-running investigation into the company’s historical financial reporting practices.

The market regulator levied a penalty of Rs 15.95 crore on Suzlon, while former executive Vinod R Tanti was fined Rs 5.75 crore and Girish R. Tanti was penalised Rs 5.45 crore. Former group CFO Kirti J. Vagadia was fined Rs 1.5 crore, while former CFO Amit Agarwal was directed to pay Rs 30 lakh.

Advertisement

Sebi action followed a forensic audit and investigation covering multiple financial years after the regulator received a complaint alleging irregularities in dealings involving subsidiaries and associate entities.


The regulator concluded that certain transactions between Suzlon and its subsidiaries had the effect of overstating profits and strengthening the appearance of the company’s financial position.
Among the issues examined were transfers of businesses and investments among group entities, accounting treatment of contingent liabilities, impairment reversals and disclosures made in financial statements.According to Sebi, some transactions involving subsidiaries resulted in substantial accounting gains being recorded without reflecting the underlying economic reality of the arrangements. The regulator also questioned the treatment of certain liabilities and fund flows between group entities, concluding that the company’s disclosures did not present a true and fair picture of its financial position during the period under review.

Sebi said accurate financial statements are critical because investors rely on them while assessing the health and prospects of listed companies. The regulator held that the violations warranted monetary penalties under provisions relating to disclosure norms, listing regulations and fraudulent and unfair trade practices.

Suzlon, however, has now moved to contest the findings before the appellate tribunal.

The company has undergone a significant turnaround over the past few years after overcoming a prolonged debt crisis and has emerged as one of the biggest beneficiaries of India’s renewable energy push. It recently reported strong operational performance and remains one of the country’s largest wind energy equipment manufacturers.

Advertisement

The appeal before the SAT will determine whether the regulator’s findings and penalties are upheld, modified or set aside. Until then, the Sebi order remains in force.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times.)

Continue Reading

Business

Costco notifies members of cheese bread recall over salmonella fears

Published

on

Costco notifies members of cheese bread recall over salmonella fears

A frozen cheese bread product sold at Costco is being recalled over concerns it could be contaminated with salmonella, prompting the retailer to notify customers who purchased the affected items.

Champion Foods LLC announced a voluntary recall of certain batches of Motor City Pizza Co. 5 Cheese Bread after learning that an ingredient supplier had recalled milk powder because of a potential salmonella contamination concern.

Advertisement

According to the company, the recalled milk powder was supplied to a third-party manufacturer that produces a seasoning blend used in the product’s five-cheese sauce mixture.

Costco also sent notices to members who purchased the product, saying its records indicate they, or one of their add-on members, bought Motor City Pizza Co. 5 Cheese Bread between Feb. 6 and May 29. The wholesale club advised customers not to consume the recalled product and to return it to a local Costco warehouse for a full refund.

DELI MEAT, CUCUMBERS TOP LIST OF ‘REALLY RISKY FOODS’ YOU MIGHT HAVE IN THE FRIDGE

Motor City Pizza Co. 5 Cheese Bread

Champion Foods LLC announced a voluntary recall of its Motor City Pizza Co. 5 Cheese Bread, which is sold at Costco, over potential salmonella concerns. (Champion Foods / Unknown)

The recall affects both single-pack and two-pack versions of the frozen bread product.

Advertisement

The affected single-pack product carries UPC code 8 70375 00511 1 and includes sell-by dates ranging from Feb. 4, 2027, through April 21, 2027.

The affected two-pack product carries UPC code 8 70375 00509 8 and includes sell-by dates of Feb. 3, 2027; Feb. 4, 2027; Feb. 24, 2027; Feb. 25, 2027; March 10, 2027; March 11, 2027; March 18, 2027; and March 25, 2027.

Customers shop at a Costco frozen food aisle

Costco sent a letter to members about the recalled product. (Joe Raedle/Getty Images / Getty Images)

5 OF THE TOP SOURCES OF FOODBORNE ILLNESS AND HOW TO PREVENT IT

Champion Foods said routine testing conducted by the seasoning blend manufacturer before the ingredient was used in production showed the batches tested negative for salmonella. The company said it nevertheless decided to issue the recall “out of an abundance of caution” for customer safety.

Advertisement
Costco exterior

Costco urged consumers who purchased one of the recalled products to not eat it and return it to Costco for a refund. (Joe Raedle/Getty Images / Getty Images)

Costco’s notice stated that no illnesses or injuries related to the recalled products have been reported.

Salmonella is an organism which can cause “serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems,” according to the U.S. Food and Drug Administration (FDA). Symptoms among healthy individuals may include fever, diarrhea, nausea, vomiting and abdominal pain.

 GET FOX BUSINESS ON THE GO BY CLICKING HERE

In rare and more serious cases, salmonella can spread to the bloodstream, potentially causing arterial infections, endocarditis or arthritis.  

Advertisement

FOX Business’ Bonny Chu contributed to this report.

Continue Reading

Business

How Trump’s Ukraine aid cuts undermine justice for Russian war crimes

Published

on

How Trump’s Ukraine aid cuts undermine justice for Russian war crimes


How Trump’s Ukraine aid cuts undermine justice for Russian war crimes

Continue Reading

Business

Market Trading Guide: YES Bank among two stock picks for Monday with up to 10% upside scope

Published

on

Market Trading Guide: YES Bank among two stock picks for Monday with up to 10% upside scope
Equity markets witnessed broad-based selling pressure on Friday following the IMD’s monsoon forecasts of 90% of the long-period average (LPA), raising concerns among investors. The prospect of deficient rainfall, coupled with the increasing likelihood of an El Niño weather pattern, has heightened fears of elevated food inflation in the coming months. However, the downside risk appears partially mitigated by the recent moderation in crude oil prices and bond yields. Additionally, global sentiment remains supported by expectations of a potential diplomatic breakthrough between the US and Iran, which has contributed to a rally in international markets.

Analysts say that in the near term, investor attention is expected to shift toward key domestic triggers, particularly the upcoming RBI monetary policy decision and GDP data release, which will provide further insights into the inflation trajectory and overall economic momentum.

Here are two stocks to buy on Monday

1) YES Bank – Buy | CMP: Rs 23.22 | Stop loss: Rs 22.5 | Target: Rs 25

Advertisement

Yes Bank shows strong bullish momentum as the price breaks decisively above the key horizontal resistance level at Rs 22.02. This breakout is supported by a noticeable volume expansion, confirming genuine market participation. The price is trading cleanly above the short- and long-term EMAs, which are fanning out in a bullish alignment, while the RSI rises above 60, signalling accelerating upward strength toward the descending trendline.

2) NBCC – BUY | CMP: Rs 100.3 | SL – Rs 95 | Target – Rs 110

NBCC (India) Limited exhibits a strong bullish reversal as price breaks above multiple short-term EMAs and tests the long-term blue EMA near 101.30. This upward shift is backed by a notable volume surge, indicating a clear influx of buyers at these levels. Meanwhile, the RSI has crossed above the 60 threshold, signalling accelerating positive momentum and confirming a strong structural turnaround from the recent bottom
(Virat Jagad is Sr Technical Research Analyst at Bonanza Portfolio)(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times.)

Continue Reading

Trending

Copyright © 2025